e-learning
resources
Virtual 2021
07.09.2021
New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study.
F. Bonella (Essen, Germany), M. Vegas Sanchez (Madrid, Spain), P. Millan (Badalona, Spain), E. Gottstein (Essen, Germany), . Sánchez Pernaute (Madrid, Spain), D. Castillo (Barcelona, Spain)
Source:
Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Session:
New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Session type:
Oral Presentation
Number:
2971
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Bonella (Essen, Germany), M. Vegas Sanchez (Madrid, Spain), P. Millan (Badalona, Spain), E. Gottstein (Essen, Germany), . Sánchez Pernaute (Madrid, Spain), D. Castillo (Barcelona, Spain). Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study.. 2971
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD).
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Relationships between angiogenic activity of sera from interstitial lung disease (ILD) patients and lung function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 106s
Year: 2002
Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease (CTD-ILD):a cross-sectional study and longitudinal study
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Measuring patient activation in an interstitial lung disease (ILD) population: an exploratory study
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001
The composite physiological index strongly predicts mortality in interstitial lung disease (ILD) associated pulmonary hypertension (PH-ILD)
Source: International Congress 2017 – Imaging and lung disease PH
Year: 2017
A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
The analysis of prognostic factors in patients with interstitial lung diseases
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Red cell distribution width (RDW) as a biomarker of disease severity in ILD patients
Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice
Year: 2015
Could KL-6 levels in COVID-19 help to predict lung disease ?
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021
KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Predictive factors for the incidence of lung cancer (LC) complicated in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2019 – Advances in clinical management of COPD
Year: 2019
Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients
Source: ERJ Open Res, 5 (2) 00021-2019; 10.1183/23120541.00021-2019
Year: 2019
KL-6 is a useful serum biomarker for early detection of interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept